T-cell lymphoma
Drug research and approvals for T-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 539 studies of T-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, FDA has 12 approved and 61 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 539
- Trials authorized in Canada: 4
- FDA orphan approvals: 12
- EU medicines: 2
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or…NCT07892027 · Phase 2 · University of Michigan Rogel Cancer Center · starts Nov 10, 2026
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasNCT07883135 · Phase 2 · National Research Center for Hematology, Russia · starts Sep 1, 2026
- Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07862010 · Early Phase 1 · Hematology department of the 920th hospital · starts Nov 28, 2025
- Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute…NCT07838714 · Phase 1 · Ruijin Hospital · starts May 13, 2026
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory…NCT07788118 · Phase 1 / Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 1, 2026
- CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line TherapyNCT07779018 · Phase 2 · Liping Dou · starts Apr 1, 2026
Approved 14
- RomidepsinCutaneous T-cell lymphoma · Histone deacetylase inhibitor
- Brentuximab vedotinAnaplastic large-cell lymphoma · Tubulin inhibitor
- PralatrexatePeripheral T-cell lymphoma · Dihydrofolate reductase inhibitor
- MechlorethamineMycosis fungoides · DNA inhibitor
- MogamulizumabMycosis fungoides · C-C chemokine receptor type 4 cross-linking agent
- BelinostatPeripheral T-cell lymphoma · Histone deacetylase inhibitor
- BexaroteneCutaneous T-cell lymphoma · Retinoid X receptor agonist
- MethotrexateMycosis fungoides · Dihydrofolate reductase inhibitor
- VorinostatCutaneous T-cell lymphoma · Histone deacetylase 1 inhibitor
- Denileukin diftitoxCutaneous T-cell lymphoma · Elongation factor 2 inhibitor
- MethoxsalenDNA inhibitor
- PrednisoneMycosis fungoides · Glucocorticoid receptor agonist
- Dexamethasone phosphoric acidMycosis fungoides · Glucocorticoid receptor agonist
- DexamethasoneMycosis fungoides · Glucocorticoid receptor agonist
Phase 3 12 of 22
- CyclophosphamidePeripheral T-cell lymphoma · DNA inhibitor
- DoxorubicinPeripheral T-cell lymphoma · DNA topoisomerase II alpha inhibitor
- TucidinostatPeripheral T-cell lymphoma
- VincristinePeripheral T-cell lymphoma · Tubulin inhibitor
- AzacitidinePeripheral T-cell lymphoma · DNA (cytosine-5)-methyltransferase 3A inhibitor
- GemcitabinePeripheral T-cell lymphoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
- AlemtuzumabPeripheral T-cell lymphoma · CAMPATH-1 antigen inhibitor
- CisplatinPeripheral T-cell lymphoma · DNA inhibitor
- MitoxantronePeripheral T-cell lymphoma · DNA topoisomerase II alpha inhibitor
- HypericinMycosis fungoides
- DecitabinePeripheral T-cell lymphoma · DNA (cytosine-5)-methyltransferase 3A inhibitor
- DacarbazinePeripheral T-cell lymphoma · DNA inhibitor
Phase 2 12 of 75
- LenalidomidePeripheral T-cell lymphoma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- PembrolizumabMycosis fungoides · Programmed cell death protein 1 inhibitor
- CytarabineAnaplastic large-cell lymphoma · DNA inhibitor
- PanobinostatCutaneous T-cell lymphoma · Histone deacetylase inhibitor
- RituximabAnaplastic large-cell lymphoma · B-lymphocyte antigen CD20 binding agent
- NivolumabPeripheral T-cell lymphoma · Programmed cell death protein 1 inhibitor
- TanespimycinAnaplastic large-cell lymphoma · Heat shock protein HSP90 inhibitor
- DarinaparsinPeripheral T-cell lymphoma
- BusulfanDNA inhibitor
- Mycophenolate mofetilSezary syndrome · Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusSezary syndrome · FK506-binding protein 1A inhibitor
- VinorelbineAnaplastic large-cell lymphoma · Tubulin inhibitor
Phase 1 or earlier 12 of 42
- CarfilzomibPeripheral T-cell lymphoma · 26S proteasome inhibitor
- AgatolimodMycosis fungoides · Toll-like receptor 9 agonist
- DurvalumabCutaneous T-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
- ParsaclisibPeripheral T-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
- GuanineCutaneous T-cell lymphoma
- 6-O-benzylguanineCutaneous T-cell lymphoma
- LinperlisibPeripheral T-cell lymphoma
- CarboplatinAnaplastic large-cell lymphoma · DNA inhibitor
- CyclosporineSezary syndrome · Cyclophilin A modulator
- IrinotecanAnaplastic large-cell lymphoma · DNA topoisomerase I inhibitor
- TrastuzumabMycosis fungoides · Receptor protein-tyrosine kinase erbB-2 inhibitor
- AldesleukinSezary syndrome · Interleukin-2 receptor agonist
How its trials ended
775 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 214 whose ending is known, 34% met their primary endpoint, 7% missed it and 59% stopped early.
- Completed, result not reported21928%
- Ongoing20627%
- Status unknown13618%
- Met its primary endpoint739%
- Stopped: other or unclear517%
- Stopped: enrollment or feasibility385%
- Stopped: sponsor or business decision213%
- Missed its primary endpoint142%
- Stopped: funding71%
- Stopped: lack of efficacy61%
- Stopped: safety41%
| Nov 18, 2022 | An interventional, single-arm, open-label phase II study investigating the efficacy and safety of ANTI-PD1 immunotherapy for the treatment of patients with…Libtayo (cemiplimab) | Alberta Health Services, Cross Cancer Institute | Pending |
| Feb 6, 2019 | An open-label, multi-center extension study to investigate the efficacy and safety of cobomarsen (MRG-106) following systemic treatment, in subjects with ctcl,…Cobomarsen / Fludeoxyglucose 18F | Miragen Therapeutics | Pending |
| Aug 1, 2018 | Solar: a phase 2, randomized, open-label, parallel-group, active comparator, multi-center study to investigate the efficacy and safety of cobomarsen (MRG-106)…Cobomarsen | Miragen Therapeutics | Ongoing |
| May 24, 2016 | A phase I trial of MEDI-570 in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) follicular variant and angioimmunoblastic T-cell lymphoma…MEDI-570 / Glucovision | Princess Margaret Hospital Phase I Consortium | Closed |
| Aug 7, 2024 | LymphirTreatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic… | Citius Oncology, Inc. | Approved |
| Nov 16, 2018 | AdcetrisADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including… | Seagen Inc. | Approved |
| Aug 8, 2018 | PoteligeoPOTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after… | Kyowa Kirin Pharmaceutical Development Inc. | Approved |
| Jul 3, 2014 | BeleodaqTreatment of patients with relapsed or refractory peripheral T-cell lymphoma | Acrotech Biopharma LLC | Approved |
| Aug 23, 2013 | ValchlorTopical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed… | Helsinn Birex Pharmaceuticals Ltd. | Approved |
| Aug 19, 2011 | AdcetrisThe treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy… | Seagen Inc. | Approved |
| Jun 16, 2011 | IstodaxTreatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy | Celgene Corporation | Approved |
| Nov 5, 2009 | IstodaxTreatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy | Celgene Corporation | Approved |
| Sep 24, 2009 | FolotynTreatment of patients with relapsed or refractory peripheral T-cell lymphoma | Acrotech Biopharma LLC | Approved |
| Oct 6, 2006 | ZolinzaTreatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent… | Merck & Co., Inc. | Approved |
| Dec 29, 1999 | TargretinTreatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. | Eisai, Inc. | Approved |
| Feb 5, 1999 | OntakTreatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2… | Eisai, Inc. | Approved |
| Sep 8, 2026 | Peginterferon alfa-2aTreatment of T-cell lymphoma | pharmaand GmbH | Designated |
| Apr 13, 2026 | A small molecule inhibitor of Zeste homolog 2 (EZH2)Treatment of T-cell lymphoma | Evopoint Biosciences USA, Inc. | Designated |
| Sep 12, 2025 | Allogeneic chimeric antigen receptor (CAR) T-cell therapy…Treatment of T-cell lymphoma | Nanjing Miracle Biotechnology Co., Ltd. | Designated |
| Mar 3, 2017 | LedagaChlormethine · orphan | Helsinn Birex Pharmaceuticals Ltd. | EMA ↗ |
| Mar 29, 2001 | TargretinBexarotene | H.A.C. Pharma | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA